Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Sep 8, 2023 (3 years ago)

SANDIMMUNE Oral Solution

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, NDC 0078-0110-22.

Affected NDC 0078-0110-22

Compare with the code on your package — it is the most precise check available.

Drug: Cyclosporine

Recalling firm
Novartis Pharmaceuticals Corp.
NDC code
0078-0110-22
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1174-2023 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other Cyclosporine recalls

See all
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Ongoing Failed specification Novartis Pharmaceuticals Corporation NDC 0078-0110-22 D-0144-2024
Class II · Moderate risk

Cyclosporine

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0200-2023

Other recalls by Novartis Pharmaceuticals Corp.

All 2023 recalls
Class II · Moderate risk

Diovan (valsartan)

Failed Dissolution Specifications

Ongoing Dissolution failure Novartis Pharmaceuticals Corporation NDC 0078-0359-34 D-0746-2026
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Ongoing Failed specification Novartis Pharmaceuticals Corporation NDC 0078-0110-22 D-0144-2024
Class II · Moderate risk

Neoral soft gelatin capsules

CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.

Terminated Stability / shelf life Novartis Pharmaceuticals Corporation NDC 0078-0246-15 D-1543-2022